SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.

Ignace  Vergote

Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Carrick Therapeutics (Inst); Clovis Oncology (Inst); Deciphera (Inst); Elevar Therapeutics; Genmab (Inst); GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Mersana; MSD; Novocure; Octimet (Inst); Oncoinvent; Roche; Sotio; Tesaro (Inst); Verastem (Inst); Zentalis

Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro

Jose Alejandro  Perez-Fidalgo

Consulting or Advisory Role - Ability Pharma; Amgen; AstraZeneca; Clovis Oncology; Roche; Tesaro

Speakers' Bureau - AstraZeneca Spain; GlaxoSmithKline; Ipsen; Novartis; Pfizer; PharmaMar; Roche

Patents, Royalties, Other Intellectual Property - Pending patent

Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche

Erika P.  Hamilton

Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)

Toon  Van Gorp

Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); OncXerna Therapeutics (Inst)

Research Funding - Amgen (Inst); Roche (Inst)

Travel, Accommodations, Expenses - BMS (Inst); Immunogen (Inst); MSD/Merck (Inst); Novartis (Inst); Roche (Inst)

Giorgio  Valabrega

No Relationships to Disclose

Annouschka  Laenen

No Relationships to Disclose

Amit M.  Oza

(OPTIONAL) Uncompensated Relationships - Ozmosis Research

Tally  Levy

No Relationships to Disclose

David  Cibula

Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Roche; Sotio

Jalid  Sehouli

Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva

Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro

Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro

Eva  Guerra

No Relationships to Disclose

Hye Sook  Chon

Honoraria - Curio Science; Main line health; MedSurvey

Consulting or Advisory Role - Envision Communications

Alice  Bergamini

Honoraria - AstraZeneca; GlaxoSmithKline; MSD

Travel, Accommodations, Expenses - Tesaro

Ignacio  Romero

Consulting or Advisory Role - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; Roche

Speakers' Bureau - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche

Research Funding - Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche

Dayana  Michel

Employment - Karyopharm Therapeutics

Travel, Accommodations, Expenses - Karyopharm Therapeutics

Jatin J.  Shah

Employment - Karyopharm Therapeutics

Leadership - Karyopharm Therapeutics

Stock and Other Ownership Interests  - Karyopharm Therapeutics

Bradley J.  Monk

Leadership - US Oncology

Honoraria - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoID; Clovis Oncology; Deciphera; Eisai; Elevar Therapeutics; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Starton Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics

Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoCare; ChemoID; Clovis Oncology; Deciphera; Eisai; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Sorrento Therapeutics; Sorrento Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics

Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK

Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)

Brian M.  Slomovitz

Consulting or Advisory Role - Agenus; AstraZeneca; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; GOG Foundation; Incyte; Merck; Myriad Genetics

Mansoor Raza  Mirza

Leadership - Karyopharm Therapeutics; Sera Prognostics

Stock and Other Ownership Interests  - Karyopharm Therapeutics; Sera Prognostics

Honoraria - AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab

Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Pfizer (Inst); Tesaro (Inst)

Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Ultimovacs (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro

Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup

Vicky  Makker

Honoraria - Eisai; IBM; Karyopharm Therapeutics; Merck

Consulting or Advisory Role - ArQule; Clovis Oncology; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; Karyopharm Therapeutics; Merck; Takeda

Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck

Other Relationship - IBM